small molecules
2026-04-28 | Baicalin-Wogonin Combination from TCM Scutellaria baicalensis for X-linked Gene Dosage Compensation
Baicalin selectively inhibits HDAC1/2 while wogonin activates SIRT1, creating a dual epigenetic modulation that enhances X-inactivation efficiency. This combination specifically targets the chromatin remodeling defects in tetrasomy X by promoting heterochromatin formation at supernumerary X chromosomes through coordinated histone deacetylation and H3K9me3 enrichment.
Open article ↗
2026-04-28 | Selective Estrogen Receptor Modulator Repurposing for Hormonal Imbalance
Raloxifene acts as an estrogen receptor β (ERβ) agonist while antagonizing ERα, correcting the hormonal dysregulation in tetrasomy X patients. The additional X chromosomes disrupt normal estrogen signaling ratios, and raloxifene's tissue-selective activity normalizes bone metabolism and reproductive hormone balance without adverse estrogenic effects.
Open article ↗
2026-04-28 | Curcuma longa Ar-turmerone for X-linked Oxidative Stress Mitigation
Ar-turmerone activates the Keap1-Nrf2 pathway by covalently modifying Keap1 cysteine residues, leading to Nrf2 nuclear translocation and antioxidant response element activation. In tetrasomy X, increased expression of X-linked genes creates cellular oxidative burden, which ar-turmerone addresses by upregulating SOD1, catalase, and glutathione peroxidase expression.
Open article ↗
2026-04-28 | Metformin-Rapamycin Combination for mTOR-Mediated Growth Regulation
Metformin activates AMPK to inhibit mTORC1 while rapamycin directly blocks mTORC1 kinase activity, creating synergistic suppression of the hyperactive growth signaling in tetrasomy X. This combination specifically targets the tall stature phenotype by modulating IGF-1/mTOR axis dysregulation caused by increased dosage of X-linked growth-promoting genes.
Open article ↗
2025-02-15 | Research Priorities of Individuals and Families With Sex Chromosome Aneuploidies
Sex chromosome aneuploidies (SCAs) are chromosomal variations that result from an atypical number of X and/or Y chromosomes. Combined, SCAs affect ~1/400 live births, including individuals with Klinefelter syndrome (47, XXY), Turner syndrome (45, X and variants), Double Y syndrome (47, XYY), Trisomy X (47, XXX), and rarer tetrasomies and pentasomies. Individuals with SCAs experience a wide variety of physical health, mental health, and healthcare experiences that differ from the standard population. To understand the priorities of the SCA community we surveyed participants in two large SCA registries, the Inspiring New Science in Guiding Healthcare in Turner Syndrome (INSIGHTS) Registry and the Generating Advancements in Longitudinal Analysis in X and Y Variations (GALAXY) Registry. 303/629 (48.1% response rate) individuals from 13 sites across the United States responded to the survey, including 251 caregivers and 52 self-advocates, with a range of ages from 3 weeks to 73 years old, and representation from all SCA groups (Turner syndrome, XXX, XXY, XYY, XXYY, and combined rare tetrasomies and pentasomies). Results demonstrate the priorities for physical health and emotional/behavioral health identified by the SCA community, as well as preferred types of research. All SCA subtypes indicated intervention studies as the top priority, emphasizing the need for researchers to focus on clinical treatments in response to priorities of the SCA community.
Open article ↗